30 closest matches · ranked by relevance
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Pneumonia
Primary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 38690; 27971 Extended-Spectrum Days-of-Therapy
Pneumonia
Primary: Hospital Acquired Pneumonia Occurrences — 2; 13 participants
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
VAP - Ventilator Associated Pneumonia
Primary: Total Number of Deaths in the Pre vs Post-intervention Time Periods Among Study Participants Per 1000 Mechanically Ventilated Patient Days — 72; 73 Deaths per 1000…
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Clinical Modified Intent-to-Treat (cMITT) Population — 62.7 Percentage of participants
Pneumonia
Primary: Length of Hospital Stay — 7.3; 5.8 Days
Complication of Surgical Procedure
Primary: Number of Participants With Postoperative Healthcare Acquired Infections — 108; 116 Participants
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Ventilator-Associated Pneumonia
Primary: Change in Antibiotic Usage or Exposure — 11.87; 7.76 days — p=0.26
Central Line-associated Bloodstream Infection (CLABSI) · Ventilator Associated Pneumonia
Primary: CLABSI and VAP Rates — 1.84; 2.42; 2.24; 2.47 events/1000 device days — p=<.05
Early Ventilator Associated Pneumonia
Primary: Clinical Response — 2.9; 2.9 score on a scale — p=<0.01
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
Pneumonia
Primary: Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu)…
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Primary: Day 14 All-cause Mortality Rate — 3.0; 2.7 percentage of participants
Pertussis
Primary: Evidence of Pertussis Infection in Each PEP Arm, Defined Using Clinical, Microbiologic, or Serologic Criteria. — 6; 1 participants
Pneumonia
Primary: Time to 30-day Mortality — 15; 14 days
Hospital-Acquired Bacterial Pneumonia · Ventilator-Associated Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population — 11.2; 5.9 Percentage of Participants — p=0.024
Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…
Methicillin-Resistant Staphylococcus Aureus (MRSA) · Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009
Pneumonia, Ventilator-Associated
Primary: Incidence of Ventilator-Associated Pneumonia (VAP) — 16; 27 Participants
Chronic Obstructive Pulmonary Disease
Primary: Length of Stay — 4.8; 3.2 days
Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537